News

Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 04-01-2011
Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma’s ATIR™. ATIR™ is a personalized hematology product... read more 

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

35th Annual Meeting of the EBMT

Principal Investigators of Kiadis Pharma have presented at the 35th Annual Meeting of the European Group for Blood and Marrow Transplantation in Göteborg on its lead product ATIR™

Abstacts Satellite Symposium

Satellite Symposium:  “Improving the outcomes of matched and mismatched transplants by selective allodepletion of T-cells”

 

PDF brochure with abstracts of the satellite symposium

 

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51